Valneva reports more data on Covid-19 vaccine; ClinChoice buys a CRO
Valneva presented updates on its Covid-19 vaccine, the first to get the full marketing green light in Europe, but the French biotech stopped manufacturing of it last year because of reduced order volume in the EU.
The company said it has extended the vaccine’s shelf life by three months, from 18 to 21 months. It also said the European Medicines Agency’s committee gave a positive opinion for using the vaccine, VLA2001, as a booster dose in adults 18 to 50 years old.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.